Peptides in Neuroscience

Overview

Neuropeptides are a diverse family of signaling molecules that regulate virtually every aspect of nervous system function, from pain perception and mood regulation to appetite, sleep, and memory. The human brain produces more than 100 known neuropeptides, making them the largest class of signaling molecules in the central nervous system (CNS).

Despite their biological importance, translating neuropeptides into therapeutics has been challenging. The blood-brain barrier (BBB), rapid enzymatic degradation, and complex receptor pharmacology have historically limited the development of peptide-based CNS drugs. However, advances in BBB-crossing strategies, peptide stabilization, and intranasal delivery are overcoming these barriers, and multiple neuropeptide-based therapeutics are now in clinical development.

Key Neuropeptide Systems

Opioid Peptides

Endogenous opioid peptides — endorphins, enkephalins, and dynorphins — modulate pain, reward, and stress responses through mu, delta, and kappa opioid receptors. Synthetic opioid peptide analogs have been developed as analgesics, though the opioid crisis has shifted focus toward:

• Biased agonists that produce analgesia with reduced respiratory depression and addiction potential
• Delta-opioid receptor-selective peptides for pain without mu-receptor-mediated side effects
• Peptide antagonists of the nociceptin/orphanin FQ system

Oxytocin and Vasopressin

Oxytocin (9 amino acids) and vasopressin (9 amino acids) are structurally related neuropeptides with distinct CNS functions:

• Oxytocin — Regulates social bonding, trust, and anxiety. Intranasal oxytocin is being investigated for autism spectrum disorder, social anxiety, schizophrenia, and post-traumatic stress disorder. Clinical trial results have been mixed, with variability attributed to dosing, delivery efficiency, and patient selection.
• Vasopressin — Beyond its peripheral effects on water balance, central vasopressin (through V1a and V1b receptors) modulates aggression, social behavior, and stress responses. V1b antagonists are in development for stress-related psychiatric disorders.

Orexin/Hypocretin System

Orexin-A and orexin-B (also called hypocretin-1 and -2) are neuropeptides produced by hypothalamic neurons that regulate wakefulness, arousal, and appetite. Loss of orexin neurons causes narcolepsy type 1.

• Orexin receptor antagonists — Suvorexant and lemborexant (small molecules, not peptides) validate the therapeutic potential of the orexin system for insomnia
• Orexin receptor agonists — Peptide and non-peptide orexin agonists are in development for narcolepsy, aiming to replace the deficient orexin signaling rather than managing symptoms

Neuropeptide Y (NPY) System

NPY is one of the most abundant neuropeptides in the brain, involved in appetite regulation, anxiety, and seizure control. The NPY system includes:

• Y1 receptor — Mediates anxiolytic and antidepressant effects
• Y2 receptor — Involved in appetite regulation and seizure suppression
• Y5 receptor — Contributes to feeding behavior

Selective NPY receptor agonists and antagonists are being explored for anxiety disorders, epilepsy, and obesity.

Substance P and Tachykinins

Substance P, acting through neurokinin-1 (NK1) receptors, is involved in pain transmission, inflammation, and emesis. NK1 receptor antagonists (aprepitant) are approved antiemetics. Research continues on tachykinin receptor modulators for depression, anxiety, and inflammatory pain conditions.

CGRP (Calcitonin Gene-Related Peptide)

CGRP is a 37-amino-acid neuropeptide centrally involved in migraine pathophysiology. The development of anti-CGRP therapies represents one of the most successful translations of neuropeptide biology into clinical practice:

• CGRP monoclonal antibodies — Erenumab, fremanezumab, galcanezumab target CGRP or its receptor for migraine prevention
• CGRP receptor antagonists (gepants) — Small-molecule oral antagonists (ubrogepant, rimegepant, atogepant) for acute treatment and prevention

While the antibodies and gepants are not themselves peptides, they validate CGRP as a therapeutic target and have stimulated interest in peptide-based approaches to other neuropeptide systems.

Blood-Brain Barrier Crossing Strategies

The BBB is the primary obstacle to CNS peptide delivery. Formed by tight junctions between brain endothelial cells, the BBB excludes most peptides larger than approximately 500 daltons. Strategies to overcome this barrier include:

Intranasal Delivery

Intranasal administration bypasses the BBB entirely, exploiting the olfactory and trigeminal nerve pathways to deliver peptides directly from the nasal mucosa to the brain. This approach is used clinically for oxytocin and desmopressin and is being investigated for numerous other neuropeptide therapeutics.

Receptor-Mediated Transcytosis

Conjugating peptides to ligands that bind receptors on brain endothelial cells (transferrin receptor, insulin receptor, LRP1) can exploit receptor-mediated transcytosis to shuttle therapeutic peptides across the BBB. This approach is being applied to both peptide therapeutics and peptide-based delivery vehicles.

Cell-Penetrating Peptides

Cell-penetrating peptides (CPPs) such as TAT (from HIV-1 Tat protein), penetratin, and poly-arginine sequences can facilitate translocation across biological membranes, including the BBB. CPPs are being used as delivery vectors for neuropeptides and other CNS-active molecules.

Chemical Modification

Structural modifications to improve BBB penetration include:

• Lipidation — Attaching fatty acid chains increases lipophilicity and passive BBB permeation
• Cyclization — Constraining peptide conformation can improve metabolic stability and membrane permeability
• N-methylation — Reduces hydrogen bonding capacity, improving passive membrane permeation
• Prodrug strategies — Masking polar groups to increase lipophilicity, with enzymatic unmasking after BBB crossing

Focused Ultrasound

Focused ultrasound combined with microbubble contrast agents can transiently and locally open the BBB, allowing peptide delivery to specific brain regions. This non-invasive approach is being evaluated in clinical trials for delivery of therapeutics to brain tumors and neurodegenerative disease targets.

Neurodegenerative Disease Applications

Alzheimer's Disease

Peptide approaches to Alzheimer's disease include:

• Peptide inhibitors of amyloid-beta aggregation
• Peptide-based immunotherapy targeting amyloid-beta and tau protein
• Neuroprotective peptides such as NAP (davunetide), an 8-amino-acid peptide derived from activity-dependent neuroprotective protein (ADNP)
• Peptide modulators of gamma-secretase activity

Parkinson's Disease

• Peptide-based delivery of neurotrophic factors (GDNF, neurturin) to the substantia nigra
• Neuroprotective peptides targeting alpha-synuclein aggregation
• Peptide vaccines against alpha-synuclein for disease modification

Amyotrophic Lateral Sclerosis (ALS)

Neuroprotective peptides and peptide-based gene therapy delivery systems are being investigated for ALS, though clinical development remains in early stages.

Challenges and Outlook

Neuropeptide therapeutics face unique challenges beyond BBB penetration: complex receptor pharmacology (many neuropeptides act on multiple receptor subtypes), pleiotropic effects (single neuropeptides influence multiple behaviors and physiological processes), and the difficulty of achieving region-specific drug delivery within the brain.

Nevertheless, the clinical success of CGRP-targeted migraine therapies and the advancing pipeline of orexin agonists, oxytocin formulations, and neuroprotective peptides demonstrate that neuropeptide-based therapeutics are increasingly viable. Continued advances in intranasal delivery, BBB-crossing technologies, and computational peptide design are expected to expand the range of neurological and psychiatric conditions addressable by peptide therapeutics.